Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16a-18F-fluoro-17b-estradiol PET/CT

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 50-55

  Van Kruchten, Michel ^a   De Vries, Erik F J ^a   Arts, Henriette J G ^a   Jager, Neeltina M ^a   Bongaerts, Alphons H H ^a   Glaudemans, Andor W J M ^a   Hollema, Harry ^a   De Vries, Elisabeth G E ^a   Hospers, Geke A P ^a   Reyners, Anna K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Estrogen receptor; FES PET; Imaging; Ovarian cancer

Indexed keywords

16ALPHA FLUORO 17BETA ESTRADIOL F18; CA 125 ANTIGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG; 16-FLUOROESTRADIOL; ESTRADIOL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER STAGING; CARCINOSARCOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOLOGY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; ESTRADIOL BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INTRAABDOMINAL METASTASIS; METASTASIS; OVARY CANCER; OVARY CARCINOMA; PET-CT SCANNER; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEROUS CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ESTRADIOL; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; SEX HORMONE-BINDING GLOBULIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920414577     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.147579     Document Type: Article

References (33)

1. Sieh W, Kobel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013; 14: 853-862.
2. van Kruchten M, van der Marel PW, Arts HJG, et al. Frequency and prognostic value of hormone receptor expression in epithelial ovarian cancer [abstract]. Cancer Res. 2013; 73(suppl 1): 4768.
3. Hasan J, Ton N, Mullamitha S, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer. 2005; 93: 647-651.
4. Argenta PA, Thomas SG, Judson PL, et al.Aphase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009; 113: 205-209.
5. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer: long-term results of a phase II study. Oncology. 2004; 66: 112-117.
6. Wilailak S, Linasmita V, Srisupundit S. Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs. 2001; 12: 719-724.
7. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002; 8: 2233-2239.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-784.
9. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012; 30: 587-592.
10. Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30: 2601-2608.
11. van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013; 14: e465-e475.
12. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006; 24: 2793-2799.
13. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001; 19: 2797-2803.
14. 18F]fluoroestradiol. Appl Radiat Isot. 1996; 47: 395-399.
15. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010; 37: 181-200.
16. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004; 45: 1519-1527.
17. 18Ffluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol. 2011; 38: 969-978.
18. Burges A, Bruning A, Dannenmann C, et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet. 2010; 281: 511-517.
19. De Stefano I, Zannoni GF, Prisco MG, et al. Cytoplasmic expression of estrogen receptor beta (ERb) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol. 2011; 122: 573-579.
20. Jongen V, Briet J, de Jong R, et al. Expression of estrogen receptoralpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009; 112: 537-542.
21. Finn RS, Press MF, Dering J, et al. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER-2 negative metastatic breast cancer. Clin Cancer Res. 2014; 20: 736-743.
22. 18F-fluoro-17b-estradiol PET. J Ovarian Res. 2009; 2: 7-16.
23. van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012; 53: 182-190.
24. 18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001; 42: 679-684.
25. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988; 169: 45-48.
26. 18F]fluoro-17b-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996; 2: 933-939.
27. 18F-fluoroestradiol. J Nucl Med. 2008; 49: 367-374.
28. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995; 36: 1766-1774.
29. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogenreceptor- positive breast cancer. Breast Cancer Res Treat. 2009; 113: 509-517.
30. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol. 1996; 62: 4-6.
31. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991; 68: 269-271.
32. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007; 13: 3617-3622.
33. Argenta PA, Um I, Kay C, et al. Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol. 2013; 131: 368-373.